Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640273 | 0.83 | DGAT1 (0.39) | DGAT1BRD4CREBBP | |
| SCHEMBL30720875 | 0.80 | MAPT (0.44) | DGAT1MAPTBRD4CREBBPNPSR1 | |
| SCHEMBL30079620 | 0.79 | ALDH1A1 (0.33) | DGAT1MAPT | |
| SCHEMBL7070391 | 0.79 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL3028008 | 0.76 | DGAT1 (0.38) | DGAT1MAPT | |
| SCHEMBL13560502 | 0.75 | DGAT1 (0.35) | DGAT1MAPTNPSR1 | |
| SCHEMBL2083830 | 0.75 | DGAT1 (0.37) | DGAT1BRD4CREBBP | |
| SCHEMBL3528522 | 0.74 | DGAT1 (0.36) | DGAT1BRD4CREBBP | |
| SCHEMBL16100391 | 0.74 | NSD2 (0.37) | DGAT1 | |
| SCHEMBL15544850 | 0.73 | BRD4 (0.37) | DGAT1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739393-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2025014788-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | WO | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | ACIN1, REV1, NFATC1 | DGAT1 3822/4885MAPT 2556/4885BRD4 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.